{"id":178669,"date":"2026-01-30T14:40:00","date_gmt":"2026-01-30T19:40:00","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=178669"},"modified":"2026-01-30T14:40:35","modified_gmt":"2026-01-30T19:40:35","slug":"dr-lal-pathlabs-ltd-sees-share-price-gain-at-market-close","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-sees-share-price-gain-at-market-close\/","title":{"rendered":"Dr. Lal PathLabs Ltd sees share price gain at market close"},"content":{"rendered":"\n<p><strong>Dr. Lal PathLabs Limited<\/strong> (NSE:LALPATHLAB) shares closed at \u20b91,409.50 at today\u2019s market close, reflecting an intraday increase of 1.02% with an observed session high of \u20b91,420.00 and a session low of \u20b91,379.20.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Financial Summary<\/strong><\/h2>\n\n\n\n<p>For the quarter ended December 31, 2025 (Q3 FY26), Dr. Lal PathLabs Limited reported consolidated revenue from operations of \u20b9660 crore, up 10.6% from \u20b9597 crore in the corresponding quarter of the previous fiscal year. EBITDA before exceptional items rose 16.3% to \u20b9179 crore with a margin of 27.2% compared with the prior period. Profit after tax (PAT) for Q3 FY26 was \u20b991 crore, down from \u20b998 crore in Q3 FY25, resulting in a margin of 13.9%. The quarter included an exceptional expense of \u20b930.1 crore related to new labor code implementation. For the nine months ended December 31, 2025 (9M FY26), revenue was \u20b92,060 crore versus \u20b91,859 crore in the prior year, and PAT was \u20b9378 crore compared with \u20b9337 crore previously. Basic EPS for the quarter was 5.4 compared with 5.8 in the year-ago quarter. Total expenses, including material consumed and employee benefits, increased in line with revenue growth.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"752\" height=\"484\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-132.png\" alt=\"\" class=\"wp-image-178670\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-132.png 752w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/image-132-300x193.png 300w\" sizes=\"auto, (max-width: 752px) 100vw, 752px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Operational Performance<\/strong><\/h2>\n\n\n\n<p>Management furnished operational data showing that the company\u2019s nationwide diagnostic network continued regular activity with test volumes supporting the revenue increase. As of the latest published data, the network comprised approximately 298 clinical laboratories, over 6,600 patient service centers, and more than 12,000 pickup points across India. Operational performance metrics in the earnings materials indicate year-over-year growth in service volumes across key test categories, contributing to top-line results.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Management Commentary<\/strong><\/h2>\n\n\n\n<p>Management stated that revenue growth in Q3 FY26 was driven by ongoing demand across both routine diagnostic services and specialized test offerings. Management also noted that cost control efforts contributed to margin resilience before exceptional items. The company said that the exceptional impact of the new labor code on gratuity and leave liabilities affected profitability for the quarter. Management reiterated that underlying demand for diagnostic tests remained stable, with contributions from bundled test packages.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Guidance and Outlook<\/strong><\/h2>\n\n\n\n<p>In commentary around the earnings release, management reiterated forward-looking statements on its strategic priorities, including continued investments in technology, service delivery enhancements, and capacity optimization across its laboratory network. The company\u2019s official release contains customary safe harbor statements noting risks and uncertainties that could affect future performance. Management also reaffirmed that capital allocation would balance expansion with operational efficiency without providing specific numerical targets for upcoming quarters.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Other Disclosures<\/strong><\/h2>\n\n\n\n<p>The Board of Directors declared a third interim dividend of \u20b93.5 per equity share for the quarter ended December 31, 2025, with a specified record date. The company also noted cash and bank balances of \u20b91,411 crore as of December 31, 2025, indicating a liquidity position at quarter-end. Additionally, the company\u2019s financial results disclosure referenced completion of a 1:1 bonus share issue in late 2025, doubling the number of equity shares.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Lal PathLabs Limited (NSE:LALPATHLAB) shares closed at \u20b91,409.50 at today\u2019s market close, reflecting an intraday increase of 1.02% with an observed session high of \u20b91,420.00 and a session low of \u20b91,379.20. Financial Summary For the quarter ended December 31, 2025 (Q3 FY26), Dr. Lal PathLabs Limited reported consolidated revenue from operations of \u20b9660 crore, [&hellip;]<\/p>\n","protected":false},"author":2399,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1941,392,5747,5],"tags":[15213,8160,15185,10089],"class_list":["post-178669","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-analysis","category-earnings","category-healthcare-stocks","category-latest","tag-dr-lal-pathlabs","tag-healthcare-services","tag-q3fy26-results","tag-quarterly-earnings"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":139887,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-limited-q3-fy23-net-profit-down-by-8\/","url_meta":{"origin":178669,"position":0},"title":"Dr. Lal PathLabs Limited Q3 FY23; Net Profit  Down By 8%","author":"Hardik Bhandare","date":"February 2, 2023","format":false,"excerpt":"Dr. Lal PathLabs Limited (NSE: LALPATHLAB) reported a Revenue from Operations of \u20b9489.4 Crores, a decline of 1.5% from the previous year. The Consolidated Net Profit for the business also decreased by 8% year over year, to \u20b953.6 Crore from \u20b958.2 Crore. Earnings per Share is \u20b96.35 for this quarter.","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/d427301c-d109-4f48-a9da-30a0d5071d90-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":145759,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-dr-lal-pathlabs-limited-for-q4-fy23\/","url_meta":{"origin":178669,"position":1},"title":"Earnings Summary Of Dr. Lal Pathlabs Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 11, 2023","format":false,"excerpt":"Dr. Lal Pathlabs Limited is a healthcare diagnostics service provider headquartered in India. The company offers a wide range of diagnostic and related healthcare tests and services, including pathology, microbiology, imaging, and genetic testing. Dr. Lal Pathlabs operates through a network of over 200 clinical laboratories and more than 2,800\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-12.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172310,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-q2-fy26-earnings-results\/","url_meta":{"origin":178669,"position":2},"title":"Dr Lal Pathlabs Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 11, 2025","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Lal Pathlab Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Lal-Pathlab-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":143002,"url":"https:\/\/alphastreet.com\/india\/earnings-dr-lal-path-labs-ltd-nselalpathlab-q3fy23-results-out-total-income-fell-2-yoy\/","url_meta":{"origin":178669,"position":3},"title":"Earnings | Dr Lal Path Labs Ltd (NSE:LALPATHLAB): Q3FY23 Results Out; Total Income fell 2% YoY","author":"Divyansh_Kasana","date":"February 28, 2023","format":false,"excerpt":"Dr Lal Path Labs Ltd (NSE:LALPATHLAB) is a leading diagnostic services provider in India. The company was founded in 1949 by Dr. S.K. Lal and is currently headquartered in New Delhi, India. Dr Lal Path Labs operates a network of over 200 clinical laboratories, more than 2,600 patient service centers,\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":169027,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4fy25-81-rise-in-profits\/","url_meta":{"origin":178669,"position":4},"title":"Dr Lal Pathlabs Ltd Q4FY25; 81% rise in Profits","author":"Divyansh_Kasana","date":"July 7, 2025","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/L.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":165284,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q2fy25-18-rise-in-profits\/","url_meta":{"origin":178669,"position":5},"title":"Dr Lal Pathlabs Ltd Q2FY25; 18% rise in Profits","author":"Divyansh_Kasana","date":"October 29, 2024","format":false,"excerpt":"Dr. Lal PathLabs Limited is one of India\u2019s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/pa.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2399"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=178669"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178669\/revisions"}],"predecessor-version":[{"id":178675,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/178669\/revisions\/178675"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=178669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=178669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=178669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}